MHS
BCRX icon

M Holdings Securities’s BioCryst Pharmaceuticals BCRX Stock Holding History

M Holdings Securities’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$252K Buy
15,928
+1,874
+13% +$25.5K 0.02% 222
2021
Q1 		$143K Buy
+14,054
New +$145K 0.01% 479

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

M Holdings Securities's BCRX Position: Q2 2021 in Review

M Holdings Securities increased its BioCryst Pharmaceuticals (BCRX) stake by 13% in Q2 2021, buying an estimated $25.5K and bringing the position to 15,928 shares worth $252K. The position accounts for 0.02% of the portfolio, ranked #222.

M Holdings Securities first reported a position in BCRX in Q1 2021 and has held it in 2 quarters since. 195 funds tracked by Wall St. Rank hold BCRX as of Q2 2021.

  • M Holdings Securities held 15,928 shares of BioCryst Pharmaceuticals worth $252K as of Q2 2021.
  • M Holdings Securities bought 1,874 BioCryst Pharmaceuticals shares in Q2 2021, an estimated $25.5K.
  • BioCryst Pharmaceuticals made up 0.02% of M Holdings Securities's portfolio in Q2 2021, its #222 holding.
  • M Holdings Securities first reported a position in BioCryst Pharmaceuticals in Q1 2021 and has held it in 2 quarters since.
  • 195 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2021.

Based on M Holdings Securities's 13F filing for Q2 2021, filed 19 Aug 2021.